WO1997033573A1 - Nasal administration of agents for treatment of delayed onset emesis - Google Patents
Nasal administration of agents for treatment of delayed onset emesis Download PDFInfo
- Publication number
- WO1997033573A1 WO1997033573A1 PCT/US1997/003974 US9703974W WO9733573A1 WO 1997033573 A1 WO1997033573 A1 WO 1997033573A1 US 9703974 W US9703974 W US 9703974W WO 9733573 A1 WO9733573 A1 WO 9733573A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- daily dosage
- day
- administered
- hours
- mcp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Definitions
- the present invention is directed to a method for treating an emetogenic reaction. More particularly, the present invention is directed to a method for treating a delayed onset emetogenic reaction, most typically associated with chemotherapy.
- Emetogenic reaction refers to vomiting (i.e. actual vomiting or dry heaving or dry retching) and/or to nausea.
- the emetogenic reaction is most commonly encountered in response to chemotherapeutic agents such as bleomycin, vincristine, vinblastine, adriamycin, etoposide, methotrexate, doxorubicin, cyclophosphar ⁇ ide, 5-fluorouracil, cisplatin and some combinations thereof.
- chemotherapeutic agents such as bleomycin, vincristine, vinblastine, adriamycin, etoposide, methotrexate, doxorubicin, cyclophosphar ⁇ ide, 5-fluorouracil, cisplatin and some combinations thereof.
- chemotherapeutic agents such as bleomycin, vincristine, vinblastine, adriamycin, etoposide, methotrexate, doxorubicin, cyclophosphar ⁇ ide, 5-fluorouracil, cisplatin and some combinations thereof.
- Acute emesis and delayed emesis typically include vomiting episodes (actual and/or dry heaving or dry retching) and/or fee li n gs of nausea. However, in acute emesis, the vomiting and/or nausea occur within the first 24 hours after
- Delayed emesis is a distinct syndrome from acute emesis occurring more than 24 hours after the administration of anticancer agents, especially, cisplatin.
- MCP ns nasal spray formulation of MCP
- Xt is a further object of the present invention to provide a method for controlling delayed emesis induced by chemotherapy using MCP nasal spray administered intranasally after the first 24 hours of completing chemotherapy.
- the presently disclosed invention is directed to a method for treating and controlling delayed emesis by using a
- the MCP nasal spray dosage form is formulated to contain a therapeutically effective amount of MCP such that upon administration by the intranasal route, a therapeutically effective amount of MCP is delivered to the patient.
- the therapeutically effective amount of MCP is chosen to minimize the severity and incidence of untoward side-effects and drug- interactions encountered with MCP.
- the MCP nasal spray formulation was given (to the patients indicated in Figures 1(a) and 1(b)) as 1 puff per nostril
- the above formulation was sterile with a bacteria count of 10 below the level allowed by the U.S.P. on a per ml basis. In addition, pathogens were absent.
- the pH of the above formulation was about 4.0.
- Typical MCP nasal spray dosage forms are solutions or suspensions that can be administered as a nasal spray.
- the MCP nasal spray dosage formulation contains the active agent in any suitable form e.g. salt, as the hydrochloride etc.
- the MCP nasal spray dosage formulation typically also contains pH adjusters, emulsifiers or dispersing agents, buffering agents, preservatives and wetting agents as are known to those skilled in the art. See REMINGTON'S PHARMACEUTICAL
- the MCP nasal spray dosage formulation is isotonic.
- a typical MCP nasal spray formulation is in solution form having a light amber color and being non-cloudy to the naked eye with an pH of between about 3.0 - 5.0.
- the typical formulation may contain benzyl alcohol of at least about 13.5 mg/ml containing practically no impurities as determined by high pressure liquid chromatography (HPLC) and having a bacterial count of less than 250 ufc/ml and free of pathogens sufficient to form an acceptable pharmaceutical nasal spray dosage form.
- HPLC high pressure liquid chromatography
- the solvent is typically purified water suitable for use in nasal spray dosage forms or any equivalent water (e.g. injectable water) that is allowed for use in such nasal dosage forms. See REMINGTON'S PHARMACEUTICAL SCIENCES, any edition from 1980 - 1996.
- a typical dose is that dose which is therapeutically effective and whi.ch mi.ni.mi.zes si.de- effects and drug interactions, for example, in patients receiving chemotherapy.
- a typical dosage of MCP nasal spray for the treatment and control of delayed onset emesis depends upon the degree and severity of delayed emesis experienced by a typical patient (e.g. chemotherapy induced delayed emesis) .
- the dosage of MCP nasal spray may be varied between about 40 mg/day to about 120 mg/day. Above about 120 mg/day, the dosage may be undesirable due to untoward side effects experienced by patients receiving more than about 120 mg/day from the MCP nasal spray dosage form.
- MCP nasal spray is 60 mg/day typically given as 20mg three times a day (i.e. 2 puffs of 10 mg/0.1 ml of MCP nasal spray, one puff per nostril) .
- the weight of the patient may also affect the dosage to be administered.
- a dose of between about 1.95 mg/kg to about 3.90 mg/kg is given to an patient experiencing delayed emesis (e.g. chemotherapy induced delayed emesis) .
- a preferred dosage is about 0.8 mg/kg.
- the aforementioned dosages for the treatment and control of delayed emesis are given after 24 hours from the time that the chemotherapeutic regimen cycle has been administered.
- the MCP nasal spray is administered starting at about 4:00 pm on day 1 - day 1 , typically, in three or four equal dosages at three or four equal time intervals, respectively. However, the dosage may be given during waking hours so as not to wake the patient.
- the MCP nasal spray dosage form is administered intranasally and is given in addition to medications administered for the treatment and control of acute emesis. All references cited within this patent application are incorporated herein by reference in their entirety and for all purposes.
- Table I indicates the characteristics of patients that received metoclopramide nasal spray alone or metoclopramide nasal spray (MCP ns) and dexamethasone (DXM) for controlling delayed emeses induced by chemotherapy.
- Primary disease site indicates primary location of cancer.
- Table II indicates the chemotherapy regimen that each of the patients received on day 0. TABLE II - CHEMOTHERAPY REGIMEN (administered on day 0 )
- Table III indicates the vomiting, retching and nausea reported in each patient during days 1 through 6 following chemotherapy on day 0. Note that MCP nasal spray (60mg/day) indicates administration of a MCP nasal spray formulation per
- the MCP nasal spray formulation was given as 1 puff per nostril (i.e. 2 puffs at lOmg/puff (lOmg/O.lml and
- Patient No. 2 was not included because he received fractionation of chemotherapy, he was treated wit MCP ns and he had no vomiting retching or nausea (complete response)
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT97915060T ATE489137T1 (en) | 1996-03-14 | 1997-03-13 | NASAL ADMINISTRATION OF SUBSTANCES FOR THE TREATMENT OF TARDIVE EMESIS |
UA98105338A UA57733C2 (en) | 1996-03-14 | 1997-03-13 | Method for prophylactic management of delayed emesis by the use of metoclopramide nasal spray |
CA002248968A CA2248968C (en) | 1996-03-14 | 1997-03-13 | Nasal administration of agents for treatment of delayed onset emesis |
NZ331991A NZ331991A (en) | 1996-03-14 | 1997-03-13 | Nasal administration of metoclopramide for treatment of delayed onset emesis |
AU22102/97A AU707467B2 (en) | 1996-03-14 | 1997-03-13 | Nasal administration of agents for treatment of delayed onset emesis |
EE9800295A EE03665B1 (en) | 1996-03-14 | 1997-03-13 | Metoclopramide nasal spray formulation for use in the prevention of delayed emesis |
DE69740060T DE69740060D1 (en) | 1996-03-14 | 1997-03-13 | NASAL ADMINISTRATION OF SUBSTANCES FOR THE TREATMENT OF THE TARDIVES EMESIS |
SK1259-98A SK282695B6 (en) | 1996-03-14 | 1997-03-13 | Use of metoclopramide |
IL12619997A IL126199A (en) | 1996-03-14 | 1997-03-13 | Nasal pharmaceutical compositions for the prophylaxis of delayed emesis |
EP97915060A EP0891186B1 (en) | 1996-03-14 | 1997-03-13 | Nasal administration of agents for treatment of delayed onset emesis |
JP9532838A JP2000507234A (en) | 1996-03-14 | 1997-03-13 | Intranasal administration of treatment for delayed onset vomiting |
DK97915060.4T DK0891186T3 (en) | 1996-03-14 | 1997-03-13 | Nasal administration of agent for the treatment of delayed vomiting |
PL97328940A PL328940A1 (en) | 1996-03-14 | 1997-03-13 | Rhinal application of agents used in treating delayed paroxysmal vomiting |
NO984245A NO984245L (en) | 1996-03-14 | 1998-09-14 | Nasal administration of agents for the treatment of late onset emesis |
BG102780A BG102780A (en) | 1996-03-14 | 1998-09-18 | Nasal application of agents for the treatment of delayed emesis fits |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/616,121 | 1996-03-14 | ||
US08/616,121 US5760086A (en) | 1996-03-14 | 1996-03-14 | Nasal administration of agents for treatment of delayed onset emesis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997033573A1 true WO1997033573A1 (en) | 1997-09-18 |
Family
ID=24468120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/003974 WO1997033573A1 (en) | 1996-03-14 | 1997-03-13 | Nasal administration of agents for treatment of delayed onset emesis |
Country Status (24)
Country | Link |
---|---|
US (1) | US5760086A (en) |
EP (1) | EP0891186B1 (en) |
JP (1) | JP2000507234A (en) |
KR (1) | KR100420673B1 (en) |
CN (1) | CN1217657A (en) |
AT (1) | ATE489137T1 (en) |
AU (1) | AU707467B2 (en) |
BG (1) | BG102780A (en) |
CA (1) | CA2248968C (en) |
CZ (1) | CZ289797B6 (en) |
DE (1) | DE69740060D1 (en) |
DK (1) | DK0891186T3 (en) |
EE (1) | EE03665B1 (en) |
ES (1) | ES2357520T3 (en) |
IL (1) | IL126199A (en) |
NO (1) | NO984245L (en) |
NZ (1) | NZ331991A (en) |
PL (1) | PL328940A1 (en) |
PT (1) | PT891186E (en) |
RU (1) | RU2181588C2 (en) |
SK (1) | SK282695B6 (en) |
UA (1) | UA57733C2 (en) |
WO (1) | WO1997033573A1 (en) |
YU (1) | YU40398A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2980976A1 (en) * | 2011-10-10 | 2013-04-12 | Mohamed Skiba | PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF METOPIMAZINE |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770262B2 (en) * | 2000-03-30 | 2004-08-03 | Questcor Pharmaceuticals, Inc. | Nasal administration of agents for the treatment of gastroparesis |
JP2012507993A (en) * | 2008-11-11 | 2012-04-05 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Tea composition |
US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
CA3224872A1 (en) * | 2008-12-22 | 2010-07-01 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
US20110165143A1 (en) * | 2010-01-06 | 2011-07-07 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of caspases and therapeutical applications |
RU2616520C2 (en) | 2011-08-25 | 2017-04-17 | Ивоук Фарма, Инк. | Treatment of gastroparesis associated symptoms for women |
CN104606136A (en) * | 2015-01-06 | 2015-05-13 | 中国人民解放军军事医学科学院毒物药物研究所 | Metoclopramide nasal spray, as well as preparation method and application thereof |
CA3047088A1 (en) | 2016-12-15 | 2018-06-21 | Evoke Pharma, Inc. | Treatment of moderate and severe gastroparesis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
-
1996
- 1996-03-14 US US08/616,121 patent/US5760086A/en not_active Expired - Lifetime
-
1997
- 1997-03-13 UA UA98105338A patent/UA57733C2/en unknown
- 1997-03-13 AT AT97915060T patent/ATE489137T1/en active
- 1997-03-13 DK DK97915060.4T patent/DK0891186T3/en active
- 1997-03-13 YU YU40398A patent/YU40398A/en unknown
- 1997-03-13 SK SK1259-98A patent/SK282695B6/en unknown
- 1997-03-13 CZ CZ19982922A patent/CZ289797B6/en not_active IP Right Cessation
- 1997-03-13 RU RU98118578/14A patent/RU2181588C2/en active IP Right Revival
- 1997-03-13 JP JP9532838A patent/JP2000507234A/en not_active Ceased
- 1997-03-13 ES ES97915060T patent/ES2357520T3/en not_active Expired - Lifetime
- 1997-03-13 KR KR10-1998-0707237A patent/KR100420673B1/en not_active IP Right Cessation
- 1997-03-13 PL PL97328940A patent/PL328940A1/en unknown
- 1997-03-13 AU AU22102/97A patent/AU707467B2/en not_active Ceased
- 1997-03-13 EP EP97915060A patent/EP0891186B1/en not_active Expired - Lifetime
- 1997-03-13 CA CA002248968A patent/CA2248968C/en not_active Expired - Lifetime
- 1997-03-13 WO PCT/US1997/003974 patent/WO1997033573A1/en active IP Right Grant
- 1997-03-13 NZ NZ331991A patent/NZ331991A/en not_active IP Right Cessation
- 1997-03-13 EE EE9800295A patent/EE03665B1/en not_active IP Right Cessation
- 1997-03-13 PT PT97915060T patent/PT891186E/en unknown
- 1997-03-13 CN CN97194427A patent/CN1217657A/en active Pending
- 1997-03-13 IL IL12619997A patent/IL126199A/en not_active IP Right Cessation
- 1997-03-13 DE DE69740060T patent/DE69740060D1/en not_active Expired - Lifetime
-
1998
- 1998-09-14 NO NO984245A patent/NO984245L/en not_active Application Discontinuation
- 1998-09-18 BG BG102780A patent/BG102780A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2980976A1 (en) * | 2011-10-10 | 2013-04-12 | Mohamed Skiba | PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF METOPIMAZINE |
EP2581085A1 (en) * | 2011-10-10 | 2013-04-17 | Mohamed Skiba | Pharmaceutical composition for nasal administration of metopimazine |
Also Published As
Publication number | Publication date |
---|---|
IL126199A0 (en) | 1999-05-09 |
NO984245L (en) | 1998-11-11 |
JP2000507234A (en) | 2000-06-13 |
EP0891186B1 (en) | 2010-11-24 |
RU2181588C2 (en) | 2002-04-27 |
CZ289797B6 (en) | 2002-04-17 |
CA2248968C (en) | 2005-08-02 |
KR19990087763A (en) | 1999-12-27 |
DE69740060D1 (en) | 2011-01-05 |
EE9800295A (en) | 1999-02-15 |
CZ292298A3 (en) | 1999-03-17 |
NO984245D0 (en) | 1998-09-14 |
AU707467B2 (en) | 1999-07-08 |
YU40398A (en) | 2001-07-10 |
UA57733C2 (en) | 2003-07-15 |
ES2357520T3 (en) | 2011-04-27 |
EP0891186A1 (en) | 1999-01-20 |
PT891186E (en) | 2011-02-25 |
CN1217657A (en) | 1999-05-26 |
BG102780A (en) | 2000-01-31 |
US5760086A (en) | 1998-06-02 |
SK282695B6 (en) | 2002-11-06 |
PL328940A1 (en) | 1999-03-01 |
EP0891186A4 (en) | 2004-03-31 |
DK0891186T3 (en) | 2011-03-14 |
ATE489137T1 (en) | 2010-12-15 |
SK125998A3 (en) | 1999-03-12 |
EE03665B1 (en) | 2002-04-15 |
KR100420673B1 (en) | 2004-07-23 |
AU2210297A (en) | 1997-10-01 |
CA2248968A1 (en) | 1997-09-18 |
NZ331991A (en) | 2000-04-28 |
IL126199A (en) | 2004-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5436272A (en) | Treatment of obesity | |
US6103748A (en) | Method of treating an autoimmune disorder | |
EP0352025A2 (en) | Use of nalmefene in the treatment of allergic rhinitis | |
US5760086A (en) | Nasal administration of agents for treatment of delayed onset emesis | |
US5753712A (en) | Treatment of migraine headaches and formulations | |
US5972905A (en) | Use of oligosaccharides for the treatment of pruritus cutaneus associated with renal failure | |
US5661142A (en) | Anti-emetic composition | |
US5457132A (en) | Kit used in the treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers | |
EP0938319A1 (en) | Pharmaceutical compositions containing alendronate and an agent promoting gastric emptying | |
US4885312A (en) | Method for enhancing the effect of indirect-acting sympathomimetic amines | |
US4522827A (en) | Method of treating acute pancreatitis with isometheptene | |
MXPA98007474A (en) | Nasal administration of agents for the treatment of retard attack emesis | |
EP1148883B1 (en) | Use of tricyclic antidepressants for treatment of headache | |
US4663345A (en) | Etodolac for treatment of gout | |
DE3213579C2 (en) | ||
EP0140958B1 (en) | Oncolytic drug combinations | |
CA2176848A1 (en) | Use of pentoxifyllin in the treatment of multiple sclerosis | |
US6693100B1 (en) | Pharmaceutical compositions for treating psoriasis | |
US4716177A (en) | Tolrestat for inhibition of weight gain | |
US5081129A (en) | Method of treatment of anemia with seratonin antagonists | |
CN114522163A (en) | Compound preparation of benproperine for treating cough and preparation method thereof | |
IL34670A (en) | Pharmaceutical compositions containing 2-(2,6-dichlorophenyl-amino)-1,3-diazacyclopentene-(2)and/or acid addition salts thereof | |
EP1711054A1 (en) | Method and compositions for treatment of painful disorders | |
CA2167044A1 (en) | Oral administration of effective amounts of forms of hyaluronic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-403/98 Country of ref document: YU Ref document number: 97194427.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2248968 Country of ref document: CA Ref document number: 2248968 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980707237 Country of ref document: KR Ref document number: 125998 Country of ref document: SK Ref document number: PA/a/1998/007474 Country of ref document: MX Ref document number: PV1998-2922 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 331991 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997915060 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997915060 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-2922 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980707237 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1998-2922 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980707237 Country of ref document: KR |